Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520900 | 0.79 | HTR6 (0.59) | HTR6HTR2AKHKADRA2APNMT | |
| Hydrochloric Acid SCHEMBL17630885 | 0.79 | HTR6 (0.59) | HTR6HTR2AKHKADRA2APNMT | |
| SCHEMBL16385666 | 0.78 | SLC6A4 (0.55) | SMN1; SMN2GAA | |
| SCHEMBL28538188 | 0.77 | MAPT (0.49) | HTR6HTR2AKHKHTTKMT2A | |
| SCHEMBL31333875 | 0.76 | HTR6 (0.53) | HTR6HTR2AKHKADRA2APNMT | |
| SCHEMBL10036372 | 0.76 | HTR6 (0.53) | HTR6HTR2AKHKADRA2APNMT | |
| SCHEMBL519662 | 0.76 | HTR6 (0.53) | HTR6HTR2AKHKHTTADRA2A | |
| SCHEMBL6410070 | 0.74 | HTR6 (0.53) | HTR6HTR2AKHKADRA2APNMT | |
| SCHEMBL520577 | 0.73 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP19A1 | |
| SCHEMBL519626 | 0.73 | HTR6 (0.50) | HTR6HTR2AKHKADRA2APNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2015003658-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-01-15 | — | — | WO | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | ALK, EGFR, ERBB2 | HTR6 2085/4885HTR2A 3021/4885SMN1; SMN2 4557/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | HTR6 3653/4885HTR2A 2335/4885SMN1; SMN2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.